Table of contents :
| Anatomical classification : | Symptoms, signs, and syndromes :
|
Diseases of the esophagus
|
|
|
|
|
| cervical esophagus cancer |
|
|
|
| upper thoracic esophagus cancer |
|
|
|
| midthoracic esophagus cancer |
|
||
| lower thoracic esophagus cancer |
|
|
|
|
|
|
|
| none | 0 | 0 | 0 | 0 |
| portal (few) | 1 | 1 | 1 | 1 |
| portal (most) | 1 | 1 | 1 | 2 |
| periportal +/- rare portal-portal septa | 2 | 1 | 2 | 2 |
| few bridges or septa | 3 | 2 | 3 | 3 |
| numerous bridges or septa | 3 | 3 | 3 | 4 |
| incomplete cirrhosis | 4 | 4 | 4 | 5 |
| cirrhosis, definite or probable | 4 | 4 | 4 | 6 |
|
|
|
|
|
| weight gain (% increase) | 7.0 ± 3.5 % | 10.1 ± 5.3% | 15.5 ± 9.2% |
| maximum bilirubin (mg/dL) | 4.7 ± 2.9 | 7.9 ± 6.6 | 26.0 ± 15.2 |
| peripheral edema | 23% | 70% | 85% |
| ascites | 5% | 16% | 48% |
| day 100 mortality (all causes) | 3% | 20% | 98% |
|
|
|
|
|
| ascitis |
|
|
|
| encephalopathy |
|
|
|
| [albumin]plasma [g/dL] |
|
|
|
| prothrombin activity |
|
|
|
| bilirubinemia [mg/dL] |
|
|
|
| esophageal varices |
|
|
|
|
| tumor size |
|
|
| ascites |
|
|
| serum albumin |
|
|
| serum total bilirubin |
|
|
|
|
|
|
|
|
|
|
|
| 0 | single tumor |
|
normal bilirubin no portal hypertension |
|
early HCC | radical cure | hepatic
segmentectomy |
| 0 | single tumor |
|
normal bilirubin and portal hypertension |
|
|||
| 0 | single tumor |
|
abnormal bilirubin and portal hypertension |
|
liver
transplantation |
||
| 0 | <= 3 tumors all < 3 cm |
|
Child-Pugh score A or B |
|
|||
| 0 | large multinodular (> 3 nodules or multiple nodules with largest >= 3 cm) |
|
Child-Pugh score A or B |
|
intermediate HCC | palliative | TAE |
| 1 or 2 | vascular invasion or extrahepatic spread |
|
Child-Pugh score A or B |
|
advanced HCC | palliative | new agents (investigational) |
| 3 or 4 | any |
|
Child-Pugh score C |
|
end-stage HCC | symptomatic | supportive |
|
|
dose (mg/m2body surface/d) | route of administration | days of use |
| cisplatin
(Platinol) |
20 | IV drip | days 1-4 |
| IFN-a2a |
|
|
|
| doxorubicin
(Adriamycin) |
40 | IV injection | day 1 |
| 5-FU |
400 | IV drip | days 1-4 |
|
|
|
|
|
| portal circulation | right lobe | intraabdominal infections | polymicrobial, Gram+ and - |
| arterial circulation | single lobe | systemic infections | Staphylococcus
aureus |
| biliary tract | multiple in both lobes | ascending cholangitis, biliary tract obstruction | |
| cryptogenetic | right lobes | unknown |
Bacteroides
fragilis
|
| primary hepatic | traumatized or tumor area | intestinal infections | Gram - bacteria |
Other markers that are not included in standard scoring systems should also be considered. Obesity (a body-mass index of > 30) is associated with an increase in the risk of a severe clinical course by a factor of 2 to 3ref. A hematocrit above 44% is a clear risk factor for pancreatic necrosisref, although it is a poor predictor of the severity of disease. Preliminary evidence suggests that genetic factors, such as polymorphisms in the chemokine monocyte chemotactic protein 1 (MCP-1) generef, may also predict severity, although such genetic testing is not currently used in practice. Several clinical findings — including thirst, poor urine output, progressive tachycardia, tachypnea, hypoxemia, agitation, confusion, a rising hematocrit level, and a lack of improvement in symptoms within the first 48 hours — are warning signs of impending severe disease. If such symptoms develop, admission to an intensive care unit should be considered. Intensive care may also be warranted in patients at risk for rapid deterioration in their condition, including those over the age of 55 yearsref, those who need ongoing volume resuscitation or invasive monitoring of fluid status (e.g., central venous pressure monitoring), or those with renal failure or respiratory compromiseref
The prophylactic use of antibiotics in patients with
pancreatic necrosis
is supported by the guidelines of the International
Association of Pancreatology
for the surgical management of acute pancreatitisref
and the Japanese Society of Abdominal Emergency Medicine53
but is discouraged
by an expert panel of the American Thoracic Society and
other organizationsref.
No consensus was reached by the United Kingdom Working Party
on Acute Pancreatitisref.
The last 3 organizationsref1,
ref2,
ref3
favor the use of enteral nutrition over total parenteral
nutrition in patients
with severe acute pancreatitis whenever possible.
Early intervention for gallstone pancreatitis with bile-duct
obstruction
with the use of ERCP with endoscopic sphincterotomy is
consistently recommended.
|
|
|
|
|
|
|
|
| on admission | APACHE II >= 6 | 83-99 | 33-54 | 28-40 | 80-97 | 45-65 |
| APACHE II >= 8 | 68-71 | 48-67 | 30-40 | 84-87 | 53-68 | |
| APACHE II >= 10 | 52-63 | 66-81 | 32-64 | 81-89 | 63-77 | |
| IL-6 levels > 400 pg/ml | 89 | 87 | 80 | 93 | 88 | |
| at 24 hours | APACHE II >= 8 | 63 | 73 | 38 | 88 | 71 |
| CRP > 150 mg/dl | 65 | 73 | 37 | 90 | 72 | |
| PMN elastase > 300 mg/l | 93 | 99 | 97 | 98 | 98 | |
| urinary TAP > 35 nmol/l | 68 | 74 | 44 | 89 | 73 | |
| at 48 hours | APACHE II >= 8 | 56-78 | 52-64 | 30-33 | 85-88 | 58-63 |
| Ranson's score >= 3 | 75-89 | 54-71 | 37-49 | 91-96 | 62-75 | |
| modified Glasgow score >= 3 | 45-75 | 63-89 | 28-66 | 79-93 | 59-84 | |
| CRP > 150 mg/dl | 65 | 73 | 37 | 90 | 72 |
|
|
|
||||
| 0-2 | 3-4 | 5-6 | 7-8 | ||
| Ranson's score | intensive care for > 7 days and survival | 1% | 24% | 53% | NA |
| death | 3% | 16% | 40% | 100% | |
| either intensive care for > 7 days or death | 4% | 40% | 93% | 100% | |
| 0-3 | 4-6 | 7-10 | |||
| CT severity index | complications | 8% | 35% | 92% | |
| death | 3% | 6% | 17% | ||
|
|
|
|||
|
|
|
|
|
|
| diffusely enlarged pancreas | segmental pancreatic ductal narrowing | elevated serum IgG4 level | periductal lymphoplasmacytic infiltration or fibrosis | tubulointerstitial nephritis with immune deposits within tubular basement membranes |
| enhanced peripheral rim of hypoattenuation "halo" | focal pancreatic ductal narrowing | elevated serum IgG or gamma globulin level | obliterative phlebitis | pulmonary interstitial lymphoplasmacytic infiltration with IgG4+ plasma cells |
| low-attenuation mass in head of pancreas | diffuse pancreatic ductal narrowing | presence of ALA, ACA II, ASMA, or ANA | increased number of IgG4+ plasma cells in tissue | chronic sialoadenitis with IgG4+ plasma cells |
|
|
|
|
|
|
|
| I | local/resectable (T1-T2, selected T3 (those with isolated involvement of the SMV, portal vein, or hepatic artery without encasement of the celiac axis or SMA), Nx; M0) | disease is confined to the pancreas and is clearly separated from surrounding blood vessels (no encasement of celiac axis or SMA, patent superior mesenteric vein confluence with portal vein (SMPV)) |
|
surgery; postoperative chemotherapy and/or radiation may also be offered | 17 months |
| II | locally advanced/unresectable (T3, NX-1, M0). Arterial enhancement (celiac axis or SMA) or venous occlusion (SMV or portal vein). No extrapancreatic disease | disease encases or compresses surrounding blood vessels, or has directly extended into adjacent structures |
|
chemotherapy (most commonly gemcitabine-based) and/or radiation. In very rare instances, cancers that respond well to initial treatment may subsequently be surgically resected. | 8-9 months |
| III | metastatic (T1-3, NX-1, M1) | evidence of extrapancreatic spread to distant organs (liver, peritoneum, and occasionally lungs, etc.) |
|
chemotherapy (most commonly gemcitabine-based); investigational trials | 4-6 months |
|
|
|
|
| sensitivity | 0.82 (CI = 0.96-0.52) | 0.94 (CI = 1.00-0.68) |
| specificity | 0.53 (CI = 0.80-0.23) | 0.80 (CI = 0.95-0.49) |
| overall accuracy | 0.69 | 0.87 |
|
|
|
|
|
||
| A | I | Tis | N0 | M0 | A |
| T1T2 | N0 | M0 | B1 | ||
| B | II | T3T4a | N0 | M0 | B2 |
| T4b | N0 | M0 | B3 | ||
| C | III | T1T2 | N1N2N3 | M0 | C1 |
| T3T4a | N1N2N3 | M0 | C2 | ||
| T4b | N1N2N3 | M0 | C3 | ||
| D | IV | any T | any N | M1 | D |
pneumoretroperitoneum : the presence of air or gas in the retroperitoneal space retroperitoneal fibrosis (RPF) / Ormond's disease : deposition of an often asymmetric fibrous plaque in the retroperitoneal space at the level of L4-L5, of thickness varyin from some mm to 6-12 cm, reaching the external border of psoas muscles (that are rarely involved), inglobating ureter(s) and large blood vessels.
Epidemiology : retroperitoneal fibrosis occurs most commonly in the fifth and sixth decades with a 2:1 male-female predominance.
Aetiology :Symptoms & signs : dull, non-colicky pain in the back, flank, or abdomen (90%), and often causing blockage of the ureters, with resultant hydronephrosis
- idiopathic (66% : autoimmune?)
- mediastinal tuberculous adenopathy
: complete resolution after antituberculous treatmentref
- methysergide
(12%), used for vascular and migraine headache, and in this subgroup females outnumber males 2:1
- primary or metastatic malignancy in the retroperitoneum (8%) : sarcomas are the most common primary tumors, but non-Hodgkin and Hodgkin lymphomas
and ureteral cancer
have also been found. Metastases have originated from cancer of the stomach, breast, colon, carcinoid, pancreas, prostate, ovary, and cervix. The focus of tumor may be small but may induce desmoplasia that is grossly indistinguishable from benign variance of retroperitoneal fibrosis.
- peritoneal dialysis
and impaired renal function, which may result in renal failure
. Other symptoms include weight loss, non-specific gastrointestinal complaints, and uncommonly, lower extremity edema, malaise, and dysuria. Laboratory studies may be
Laboratory examinations : normal in 25% of patients, but 55% of patients will have an elevated blood urea nitrogen. Diagnosis is most commonly suggested by intravenous pyelography. The combination of medial deviation of the ureter, hydroureteronephrosis, and extrinsic ureteral compression at abdominal X-rays are highly suggestive of retroperitoneal fibrosis. CTscanning or MRI
can both define the level of ureteral involvement and depict the mass appearance of the fibrotic process. Exploratory laparotomy with multiple deep biopsies of the retroperitoneal process is an essential part of diagnosis, since foci of carcinoma may be sparse within the predominately sclerotic reaction.
Therapy : identify and deal with potential causative agents, relieve the ureteral obstruction, and reverse the inflammatory-fibrotic process. Renal obstruction may need to be relieved acutely, either by retrograde ureteral stents or by percutaneous nephrostomy tubes. Long-term resolution of ureteral obstruction most frequently has been accomplished by operative freeing of the ureters from the fibrosis (ureterolysis) and displacing them laterally or within the peritoneal cavity. Although renal function is improved in more than 90% of cases so treated, in as many as one-third of patients, ureteral obstruction recurs on the ipsilateral or contralateral side.
Prognosis for patients with nonmalignant retroperitoneal fibrosis is good. Survivals of 86-100% for several years have been reported.desmoid tumor

Polyphagia / polyphagy
Aetiology :

Ascites / hydroperitonia / abdominal or peritoneal dropsy / hydrops abdominis : effusion and accumulation of serous fluid in the abdominal cavity
|
|
|
|
|
| %body weight |
|
|
|
| general conditions :
|
thirsthy, vigile, agitated |
|
|
| radial pulse | normal and strong | rapid and weak | rapid, weak and sometimes not palpable |
| breath rate | normal | deep (may be rapid) | rapid and deep |
| anterior fontanelle | normal | normal or depressed | very depressed |
| systolic blood pressure (arterial blood pressure assessment in children is difficult due to lack of adequate brace) | normal | normal or low; orthostatic hypotension | < 90 mmHg, may be not measured |
| skin elasticity | skin folds immediately distended | skin folds distend slowly | skin folds distend very slowly |
| eyes | normal | infossated | very infossated |
| lachrymation | present | absent | absent |
| mucosae | wet | dry | very dry |
| urine flow | normal | reduced volume or dark | severe oliguria or anuria |
| capillary refilling | normal | + 2 seconds | + 3 sec |
| estimated water loss (ml/kg) | 30-50 | 60-90 | > 100 |
Fecal incontinence :
incontinence
of flatus, liquid stool, or solid stool that has an impact on
quality of
life, varying in severity from minor faecal soiling to frank
incontinence
of solid stoolref
Epidemiology : prevalence of 11-15%
in
the communityref.
These figures have to be interpreted with caution because the
relevant
studies are hampered by possible under-reporting and, more
importantly,
by a lack of a consensus definition.
Aetiology :
Burbulence : gaseousness; a group of symptoms of intestinal origin, including ..
Gastrointestinal hemorrhages

|
|
|
for |
|